Brisbane, Calif.-based biotech firm XDx Inc. on Wednesday announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock.
XDx specializes in molecular diagnostics for the monitoring of transplant rejection and autoimmune diseases.
City seeks solutions as coastal flooding could become the new normal
Bay Area murder and robbery spike reveals shortcomings of ‘defund’ argument
To commemorate that 20th anniversary of September 11, Gloss (www.instagram.com/gloss), the team behind the world’s largest arts and media company, is…
